AI Engines For more Details: Perplexity Kagi Labs You
Gut Health: Bacillus probiotics may contribute to gut health by modulating the composition of the gut microbiota, promoting the growth of beneficial bacteria, and inhibiting the growth of harmful pathogens. They can help maintain a balanced microbial ecosystem in the gut, which is essential for digestion, nutrient absorption, and immune function.
Digestive Disorders: Some studies suggest that Bacillus probiotics may be beneficial for managing certain digestive disorders, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea. They may help alleviate symptoms such as abdominal pain, bloating, and diarrhea by restoring gut microbiota balance.
Immune Support: Bacillus probiotics have been shown to stimulate the immune system and enhance immune response against pathogens. They may help strengthen the body's natural defenses, reducing the risk of infections and promoting overall immune health.
Antimicrobial Activity: Certain Bacillus species produce antimicrobial compounds, such as bacteriocins and enzymes, which can inhibit the growth of pathogenic bacteria and fungi. This antimicrobial activity may help prevent gastrointestinal infections and maintain intestinal health.
Nutrient Production: Some Bacillus species are capable of synthesizing vitamins, enzymes, and other bioactive compounds that contribute to overall health. For example, Bacillus subtilis produces vitamin K2, which plays a role in bone health and blood clotting.
Environmental Resilience: Bacillus species are known for their ability to form spores, which are resistant to harsh environmental conditions, such as heat, acidity, and drying. This resilience allows Bacillus probiotics to survive the acidic environment of the stomach and reach the intestines alive, where they can exert their beneficial effects.
Safety Considerations: While Bacillus probiotics are generally considered safe for most people, there have been rare reports of infections associated with certain strains, particularly in immunocompromised individuals. It's essential to choose probiotic supplements containing well-characterized strains with a proven safety record.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.9 | 0.3 | 2 |
| ADHD | 1.3 | 1.1 | 0.18 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.8 | -0.33 |
| Allergies | 0.6 | 0.8 | -0.33 |
| Allergy to milk products | 0.6 | -0.6 | |
| Alopecia (Hair Loss) | 1.2 | -1.2 | |
| Alzheimer's disease | 2.8 | 0.4 | 6 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 1.6 | -1.67 |
| Ankylosing spondylitis | 0.8 | 1 | -0.25 |
| Anorexia Nervosa | 2.5 | 0.3 | 7.33 |
| Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
| Asthma | 0.8 | 0.6 | 0.33 |
| Atherosclerosis | 0.8 | 0.8 | |
| Atrial fibrillation | 0.6 | 1.6 | -1.67 |
| Autism | 2.8 | 2.3 | 0.22 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.8 | 0.8 | |
| Brain Trauma | 0.6 | 0.3 | 1 |
| Breast Cancer | 0.2 | -0.2 | |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 1 | 0.8 | 0.25 |
| Cerebral Palsy | 1 | 1 | |
| Chronic Fatigue Syndrome | 1.7 | 0.2 | 7.5 |
| Chronic Kidney Disease | 1.8 | 1.8 | |
| Chronic Lyme | 0.6 | 0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.8 | 0.5 |
| Chronic Urticaria (Hives) | 0.2 | 0.2 | |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.8 | |
| Colorectal Cancer | 0.2 | 1.2 | -5 |
| Constipation | 0.8 | 0.8 | 0 |
| Coronary artery disease | 1.6 | 0.8 | 1 |
| COVID-19 | 3 | 1.2 | 1.5 |
| Crohn's Disease | 3.3 | 2.4 | 0.38 |
| cystic fibrosis | 0.6 | 0.6 | |
| deep vein thrombosis | 1.4 | 1.4 | |
| Depression | 2.5 | 2.5 | 0 |
| Dermatomyositis | 0.4 | -0.4 | |
| Endometriosis | 0.5 | 0.6 | -0.2 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.8 | 1.3 | -0.63 |
| erectile dysfunction | 0.8 | -0.8 | |
| Fibromyalgia | 0.6 | 1.5 | -1.5 |
| Functional constipation / chronic idiopathic constipation | 1 | 1.4 | -0.4 |
| gallstone disease (gsd) | 0.6 | 0.6 | 0 |
| Generalized anxiety disorder | 0.2 | 0.4 | -1 |
| Glioblastoma | 0.8 | 0.8 | |
| Gout | 0.8 | 0.8 | |
| Graves' disease | 2.1 | 0.2 | 9.5 |
| Halitosis | 0.4 | 0.3 | 0.33 |
| Hashimoto's thyroiditis | 0.2 | 2 | -9 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.8 | 1 | -0.25 |
| hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
| hyperglycemia | 0.2 | 0.6 | -2 |
| hypersomnia | 0.2 | 0.2 | |
| hypertension (High Blood Pressure | 2.4 | 2.4 | |
| Hypothyroidism | 1.6 | 1.6 | |
| IgA nephropathy (IgAN) | 0.6 | -0.6 | |
| Inflammatory Bowel Disease | 2.3 | 0.2 | 10.5 |
| Insomnia | 0.8 | 0.4 | 1 |
| Intelligence | 1 | -1 | |
| Intracranial aneurysms | 0.5 | -0.5 | |
| Irritable Bowel Syndrome | 1.4 | 1.7 | -0.21 |
| Liver Cirrhosis | 1 | 2 | -1 |
| Long COVID | 3.5 | 2.3 | 0.52 |
| Low bone mineral density | 1.6 | 0.4 | 3 |
| Lung Cancer | 1.3 | 1.3 | |
| ME/CFS with IBS | 0.2 | 0.2 | |
| ME/CFS without IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 2.8 | 1.9 | 0.47 |
| Mood Disorders | 2.7 | 2.9 | -0.07 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
| Multiple Sclerosis | 1.4 | 0.4 | 2.5 |
| Multiple system atrophy (MSA) | 0.2 | 0.2 | 0 |
| myasthenia gravis | 0.2 | -0.2 | |
| Neuropathy (all types) | 1.1 | -1.1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.4 | 2 |
| Obesity | 2.1 | 1.6 | 0.31 |
| obsessive-compulsive disorder | 1.8 | 0.4 | 3.5 |
| Osteoarthritis | 0.6 | -0.6 | |
| Osteoporosis | 0.4 | 0.4 | |
| Parkinson's Disease | 3.3 | 0.9 | 2.67 |
| Polycystic ovary syndrome | 0.6 | 0.8 | -0.33 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.2 | 0.4 | -1 |
| primary biliary cholangitis | 0.8 | -0.8 | |
| Psoriasis | 1 | 0.2 | 4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 2.9 | -0.32 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 1.2 | 1.7 | -0.42 |
| scoliosis | 0.8 | -0.8 | |
| sensorineural hearing loss | 0.6 | 0.6 | |
| Sjögren syndrome | 1.2 | 0.4 | 2 |
| Sleep Apnea | 1.2 | 0.4 | 2 |
| Stress / posttraumatic stress disorder | 1.4 | 1 | 0.4 |
| Systemic Lupus Erythematosus | 2.1 | 0.6 | 2.5 |
| Tic Disorder | 0.4 | 0.4 | |
| Type 1 Diabetes | 1 | 1.2 | -0.2 |
| Type 2 Diabetes | 1.6 | 1.9 | -0.19 |
| Ulcerative colitis | 1.9 | 0.8 | 1.37 |
| Unhealthy Ageing | 1 | 0.2 | 4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.